Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

gilead.com

Headquarters: Foster City, United States
Company type: Public company
Number of employees: 14,000+
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Gilead Sciences (Gilead)

In short: Gilead raised 2026 guidance on strong HIV sales, won drug approvals, and made key acquisitions and legal wins.

Company announcements

October 29 Gilead

Gilead announces third quarter 2026 financial results

Total product sales increased 13% to $8.3 billion while non-GAAP diluted EPS rose to $2.55. The company raised full-year revenue guidance amid strong HIV and oncology growth.

October 27 Gilead

Gilead reports Q1 2026 earnings

Sales rose 5% to $6.9 billion with strong HIV and oncology growth. Updated 2026 guidance increases revenue by $400 million while closing major acquisitions including Arcellx.

October 27 Gilead

Gilead reports FY25 total revenue of $29.4 billion with HIV sales growth driving performance

FY25 non-GAAP diluted EPS reached $8.15, up 77% YoY. The company provides FY26 guidance projecting $29.6-$30.0 billion in product sales.

October 27 Gilead

Gilead reports second-quarter 2026 results

The company reports 8% year-over-year product sales growth, raises full-year sales guidance, and highlights pipeline progress and recent acquisitions.

Media coverage

Yesterday FierceBiotech

Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials

Gilead Sciences announced on its third-quarter earnings call Oct. | Gilead Sciences announced on its...

October 29 BioSpace

Gilead Sciences Announces Third Quarter 2026 Financial Results

Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of...

October 29 The Wall Street Journal

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength

The biopharmaceutical company said it now expects full-year product sales of $31 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.

October 22 Reuters

Gilead to buy PepStar s inflammation drug program in $1.28 billion deal

Gilead Sciences said on Thursday it will acquire PepStar Therapeutics' oral inflammation drug ‌prog...

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gilead competitors & trending companies

Browse news for competitors to Gilead and other trending companies.